Verifying…
Home / Drug A–Z / Tryal Tablets

Tryal Tablets

NAFDAC Reg. No. A4-100716 · Drug

Registered with NAFDAC. Registration activeAs of 28 October 2026 · synced automatically from official sources.
Product
Tryal Tablets
NAFDAC number
A4-100716
Active ingredient
Estradiol
Strength
2 mg
Form
Tablet
Pack size
1 x 28's
Manufacturer
Not listed
Applicant (holder)
Ignite Pharma Nigeria Limited
Approved
31 Jan 2024
Status
Active View on NAFDAC ↗
Registration valid to
30 Jan 2029
WHO alerts
None found
Community reports
None
Times checked
0

What we found

  • Tryal Tablets is on the NAFDAC register with an active registration (A4-100716). A valid number alone does not prove a pack is genuine — counterfeiters copy real numbers, so also check the expiry date, seal and print quality.

Generated automatically from the NAFDAC register, WHO alerts and community data as of today. This is not medical advice. Always follow your doctor or pharmacist.

How to use Tryal Tablets

What the official label says. If a doctor prescribed it, follow the prescription. Your pack's leaflet comes first if it is different.

Serious warning: ENDOMETRIAL CANCER, CARDIOVASCULAR DISORDERS, BREAST CANCER and PROBABLE DEMENTIA Estrogen-Alone Therapy Endometrial Cancer There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens. Adding a progestin to estrogen therapy has been shown to reduce the risk of endometrial hyperplasia, which may be a precursor to endometrial cancer. …
Who it is for

Estradiol Vaginal Cream, 0.01% is indicated in the treatment of moderate to severe symptoms of vulvar and vaginal atrophy due to menopause.

How to take it and how often
  • Use of Estradiol Vaginal Cream, 0.01% alone or in combination with a progestin, should be limited to the shortest duration consistent with treatment goals and risks for the individual woman
  • Postmenopausal women should reevaluate periodically as clinically appropriate to determine if treatment is still necessary
  • For treatment of vulvar and vaginal atrophy associated with the menopause, the lowest dose and regimen that will control symptoms should be chosen and medication should be discontinued as promptly as possible
  • For women who have a uterus, adequate diagnostic measures, including directed and random endometrial sampling when indicated, should be undertaken to rule out malignancy in cases of undiagnosed persistent or recurring abnormal genital bleeding
  • Usual Dosage: The usual dosage range is 2 to 4 g (marked on the applicator) daily for one or two weeks, then gradually reduced to one half initial dosage for a similar period
  • A maintenance dosage of 1 g, one to three times a week, may be used after restoration of the vaginal mucosa has been achieved
  • NOTE: The number of doses per tube will vary with dosage requirements and patient handling
Children
  • Pediatric Use Estradiol Vaginal Cream, 0.01% is not indicated in children
  • Clinical studies have not been conducted in the pediatric population
Older adults

I. Geriatric Use There have not been sufficient numbers of geriatric patients involved in studies utilizing Estradiol Vaginal Cream, 0.01% to determine whether those over 65 years of age differ from younger subjects in their response to Estradiol Vaginal Cream, 0.01%. …

While you are taking it
  • Patient Information Physicians are advised to discuss the PATIENT INFORMATION leaflet with women for whom they prescribe Estradiol Vaginal Cream, 0.01%
  • PATIENT INFORMATION Estradiol (es-tra-DYE-ole) Vaginal Cream USP, 0.01% Read this Patient Information before you start using Estradiol Vaginal Cream, 0.01% and each time you refill
  • There may be new information
  • This information does not take the place of talking with your healthcare provider about your menopausal symptoms or your treatment. …
Talk to a doctor first if
  • Estradiol Vaginal Cream, 0.01% should not be used in women with any of the following conditions: 1
  • Undiagnosed abnormal genital bleeding. 2
  • Known, suspected, or history of cancer of the breast. 3
  • Known or suspected estrogen-dependent neoplasia. 4
  • Active DVT, PE or history of these conditions. 5
  • Active arterial thromboembolic disease (for example, stroke, MI) or a history of these conditions. 6
  • Known anaphylactic reaction or angioedema to Estradiol Vaginal Cream, 0.01%. 7. …
Medicines it may not mix with

D. Drug-Laboratory Test Interactions 1. Accelerated prothrombin time, partial thromboplastin time, and platelet aggregation time; increased platelet count; increased factors II, VII antigen, VIII antigen, VIII coagulant activity, IX, X, XII, VII-X complex, II-VII-X complex, and beta-thromboglobulin; decreased levels of anti-factor Xa and antithrombin III, decreased antithrombin III activity; increased levels of fibrinogen and fibrinogen activity; increased plasminogen antigen and activity. 2. …

Warnings

See BOXED WARNINGS . Systemic absorption may occur with the use of Estradiol Vaginal Cream, 0.01%. The warnings, precautions, and adverse reactions associated with oral estrogen treatment should be taken into account. 1. Cardiovascular Disorders An increased risk of stroke and DVT has been reported with estrogen-alone therapy. An increased risk of PE, DVT, stroke and MI has been reported with estrogen plus progestin therapy. Should any of these occur or be suspected, estrogen with or without progestin therapy should be discontinued immediately. …

Possible side effects

See BOXED WARNINGS, WARNINGS and PRECAUTIONS . Systemic absorption may occur with the use of Estradiol Vaginal Cream, 0.01%. The warnings, precautions, and adverse reactions associated with oral estrogen treatment should be taken into account. The following adverse reactions have been reported with estrogen and/or progestin therapy. 1 . Genitourinary System Abnormal uterine bleeding or spotting; dysmenorrhea or pelvic pain, increase in size of uterine leiomyomata; vaginitis, including vaginal candidiasis; change in cervical secretion; cystitis-like syndrome; application site reactions of vulvovaginal discomfort including burning and irritation; genital pruritus; ovarian cancer; endometrial h …

Pregnancy and breastfeeding

F. Pregnancy Estradiol Vaginal Cream, 0.01% should not be used during pregnancy [see CONTRAINDICATIONS ]. There appears to be little or no increased risk of birth defects in children born to women who have used estrogens and progestins as an oral contraceptive inadvertently during early pregnancy.

If you take too much

Overdosage of estrogen may cause nausea, vomiting, breast tenderness, abdominal pain, drowsiness and fatigue, and withdrawal bleeding may occur in women. Treatment of overdose consists of discontinuation of Estradiol Vaginal Cream, 0.01% therapy together with institution of appropriate symptomatic care.

If you miss a dose

Take it when you remember, unless it is nearly time for the next dose. Then skip the missed one. Never take two doses at once to make up for it. Check your leaflet, as some medicines are different.

From the official U.S. FDA label for this active ingredient. Your pack may have a different strength, so always read its leaflet. If a doctor prescribed it, follow the prescription. Ask a pharmacist if you are unsure. Label dated 2026-04-13.

Label for estradiol, the active ingredient registered with NAFDAC.

Check your pack of Tryal Tablets

Add the expiry date on your pack for a full Trust Score.

3 free checks left today Official sources: NAFDAC · WHO · U.S. FDA · Health Canada · NLM

About Tryal Tablets

What is in Tryal Tablets?

Tryal Tablets contains Estradiol (2 mg), as tablet, according to its NAFDAC registration record.

Is Tryal Tablets registered with NAFDAC?

Yes. Tryal Tablets is listed on the NAFDAC register under registration number A4-100716, and its registration is active as of 28 October 2026.

Has Tryal Tablets been flagged as fake or recalled?

No WHO falsified or substandard medical product alert currently matches Tryal Tablets in our automatically synced alert list.

How can I check that my pack of Tryal Tablets is genuine?

Run a free authenticity scan with the NAFDAC number A4-100716, your pack's expiry date and batch number to get a Trust Score, compare the pack with the NAFDAC record (ingredient, strength, form, manufacturer), and buy only from licensed pharmacies.

How do I take Tryal Tablets?

Follow your prescription or the leaflet in your pack. The official label says: Use of Estradiol Vaginal Cream, 0.01% alone or in combination with a progestin, should be limited to the shortest duration consistent with treatment goals and risks for the individual woman. Postmenopausal women should reevaluate periodically as clinically appropriate to determine if treatment is still necessary. For treatment of vulvar and vaginal atrophy associated with the m…

What is Tryal Tablets used for?

Estradiol Vaginal Cream, 0.01% is indicated in the treatment of moderate to severe symptoms of vulvar and vaginal atrophy due to menopause. (Summarised from the official U.S. FDA label for estradiol. Always follow your doctor or pharmacist.)

Patient reviews

–No reviews yet
5★
0
4★
0
3★
0
2★
0
1★
0
Have you used Tryal Tablets? Share your experience to help other patients. Sign in to review

Reviews are personal experiences from PillVera users, not medical advice. Report side effects to your doctor and to NAFDAC.